SG Americas Securities LLC Raises Holdings in Luminex Co. (NASDAQ:LMNX)

SG Americas Securities LLC lifted its holdings in shares of Luminex Co. (NASDAQ:LMNX) by 17.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,226 shares of the medical instruments supplier’s stock after purchasing an additional 3,825 shares during the period. SG Americas Securities LLC owned about 0.06% of Luminex worth $853,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Mutual of America Capital Management LLC increased its position in shares of Luminex by 22.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 1,844 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 344 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of Luminex by 3.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,180 shares of the medical instruments supplier’s stock worth $308,000 after purchasing an additional 403 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Luminex by 16.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,857 shares of the medical instruments supplier’s stock worth $78,000 after purchasing an additional 406 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Luminex by 30.9% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,163 shares of the medical instruments supplier’s stock worth $87,000 after purchasing an additional 747 shares during the last quarter. Finally, Swiss National Bank increased its position in shares of Luminex by 1.4% in the 1st quarter. Swiss National Bank now owns 78,600 shares of the medical instruments supplier’s stock worth $2,164,000 after purchasing an additional 1,100 shares during the last quarter. 80.41% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:LMNX opened at $36.40 on Friday. The company has a quick ratio of 2.40, a current ratio of 4.00 and a debt-to-equity ratio of 0.04. Luminex Co. has a fifty-two week low of $17.34 and a fifty-two week high of $40.21. The firm has a 50-day simple moving average of $32.51 and a 200 day simple moving average of $29.16. The company has a market cap of $1.67 billion, a PE ratio of -242.65 and a beta of 0.67.

Luminex (NASDAQ:LMNX) last announced its quarterly earnings data on Monday, May 4th. The medical instruments supplier reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02. Luminex had a negative net margin of 1.81% and a negative return on equity of 1.25%. The business had revenue of $90.40 million during the quarter, compared to the consensus estimate of $82.30 million. During the same quarter in the prior year, the firm earned $0.07 EPS. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. As a group, research analysts forecast that Luminex Co. will post 0.25 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, July 9th. Shareholders of record on Thursday, June 18th were paid a dividend of $0.09 per share. This represents a $0.36 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date of this dividend was Wednesday, June 17th. Luminex’s payout ratio is -171.43%.

Several equities research analysts have recently weighed in on the stock. ValuEngine downgraded shares of Luminex from a “buy” rating to a “hold” rating in a research report on Friday, May 1st. BidaskClub downgraded shares of Luminex from a “strong-buy” rating to a “buy” rating in a research report on Friday.

In other Luminex news, SVP Richard W. Rew II sold 11,175 shares of the business’s stock in a transaction dated Friday, July 17th. The shares were sold at an average price of $36.93, for a total transaction of $412,692.75. Following the completion of the transaction, the senior vice president now directly owns 43,984 shares of the company’s stock, valued at approximately $1,624,329.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Nancy Fairchild sold 69,282 shares of the business’s stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $37.85, for a total transaction of $2,622,323.70. Following the transaction, the senior vice president now directly owns 58,483 shares of the company’s stock, valued at $2,213,581.55. The disclosure for this sale can be found here. Insiders have sold a total of 461,819 shares of company stock valued at $15,528,094 over the last three months. 9.40% of the stock is currently owned by company insiders.

About Luminex

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.

Read More: Cost of Capital

Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.